nebokitug subcutaneous (CM-101 subcutaneous) / ChemomAb - LARVOL DELTA

TARGETING CCL24 RESTORES MST1 EXPRESSION: A MECHANISTIC INSIGHT FROM THE SPRING TRIAL (AASLD 2025) - P2 | "Nebokitug treatment in PSC patients leads to a significant dose-dependent increase in MST1, correlating with CCL24 target engagement and reduction in LSM. These results from the SPRING trial suggest that MST1 may serve as a PD biomarker of nebokitug activity and further support its anti-inflammatory mechanism of action."

Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • ABCB4 • MST1

Chemomab Therapeutics Announces $10 Million Private Placement (GlobeNewswire) - "Chemomab Therapeutics Ltd...today announced that it has entered into a securities purchase agreement for a private investment in public equity ('PIPE') that is expected to result in gross proceeds of approximately $10 million to the Company, before deducting capital market advisor fees and offering expenses...Chemomab expects that the net proceeds from the PIPE will extend its cash runway to fund its operations through the beginning of 2026, an extension of approximately one year from current projections, which should fund the Company for approximately one year after the completion of two major milestones expected in early 2025...The Company intends to use the net proceeds from the PIPE, together with the Company's existing cash and cash equivalents, to fund its development programs for CM-101, and for general corporate purposes and working capital."

Financing • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Systemic Sclerosis

­­Ex-vivo translational assay of hepatic stellate cells using patient-derived serum characterizes the anti-fibrotic activity of CM-101 (EASL-ILC 2024) - P2a | "A serum-based ex-vivo assay derived from MASH patients treated with CM-101 restored HSC activation. Additionally, a protein signature generated from CCL24-activated HSC predicted PSC disease and its severity, underscoring the relevance of this translational assay to PSC. These findings support CM-101's mode of action in liver fibrosis and may serve as a translational tool in the ongoing clinical trial in PSC."

Preclinical • Fibrosis • Hepatology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

­­Ex-vivo translational assay of hepatic stellate cells using patient-derived serum characterizes the anti-fibrotic activity of CM-101 (EASL-ILC 2024) - P2a | "A serum-based ex-vivo assay derived from MASH patients treated with CM-101 restored HSC activation. Additionally, a protein signature generated from CCL24-activated HSC predicted PSC disease and its severity, underscoring the relevance of this translational assay to PSC. These findings support CM-101's mode of action in liver fibrosis and may serve as a translational tool in the ongoing clinical trial in PSC."

Preclinical • Fibrosis • Hepatology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis

Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies. (PubMed, Drug Saf) - P1, P1b | "In healthy volunteers and patients with MASLD without evidence of MASH, IV and SC CM-101 was well tolerated at doses ranging from 0.75 mg/kg to10.0 mg/kg and engaged its target (i.e., CCL24), indicating therapeutic potential in treating inflammatory and fibrotic diseases."

Journal • P1 data • Fibrosis • Hepatology • Immunology • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • Scleroderma • Systemic Sclerosis

Chemomab Therapeutics to Present at Upcoming Scientific Conferences (PRNewswire) - "Chemomab Therapeutics Ltd...announced the company will present at major U.S. scientific conferences in November, including an oral presentation on primary sclerosing cholangitis and a poster at the AASLD The Liver Meeting 2023, as well as a poster presentation on the role of Chemomab's CCL24 target in manifestations of systemic sclerosis at the American College of Rheumatology Convergence 2023. Further details of the presentations will be released in November."

Clinical data • Immunology • Systemic Sclerosis

Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=8 | Completed | Sponsor: ChemomAb Ltd.

New P1 trial • Fibrosis • Hepatology • Immunology • Non-alcoholic Steatohepatitis • Scleroderma • Systemic Sclerosis

The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects (clinicaltrials.gov) - P1b | N=16 | Completed | Sponsor: ChemomAb Ltd.

New P1 trial • Hepatology • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis

Chemomab Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update (PRNewswire) - "At a poster presentation at the EULAR European Congress of Rheumatology (June 1-4, Copenhagen, DK), Chemomab collaborator Professor Francesco Del Galdo...presented a poster further supporting the role of CCL24 as a therapeutic target for systemic sclerosis. This study, which examined the role of CCL24 in longitudinal cohorts of diffuse cutaneous SSc patients, reported elevated serum levels of CCL24 in these patients and showed that high circulating CCL24 levels were correlated with disease activity..."

Media quote

Data Supporting Role of Chemomab’s Novel Therapeutic Target CCL24 in Systemic Sclerosis Presented at EULAR 2022 (PRNewswire) - "The study, which was conducted in the laboratory of Professor Francesco Del Galdo...examined the role of CCL24 in longitudinal diffuse cutaneous systemic sclerosis (dcSSc) patient cohorts by correlating serum levels of CCL24 to disease activity markers and disease progression."

Media quote

Chemomab Therapeutics Ltd. (NASDAQ: CMMB) Announces Findings Supporting Use of CM-101 as A Systemic Sclerosis Treatment (BioPharma Journal) - "Also, on March 12, 2022...Francesco Del Galdo presented 'CCL24 as a Marker of Worse Prognosis in diffuse cutaneous SSc: a Promising Novel Biological Target' during the 7th Systemic Sclerosis World Congress.'...Del Galdo said, 'This translational study is the first to demonstrate that high CCL24 levels in patients with diffuse cutaneous systemic sclerosis are correlated with disease activity and a worse prognosis, as reflected by high fibrotic activity and the deterioration of lung function over time.'"

Media quote